FIELD: biotechnology and medicine.
SUBSTANCE: present invention relates to the field of biotechnology and medicine, namely to monoclonal antibodies or their antigen-binding fragments that specifically bind to CSF-1R (colony-stimulating factor 1 receptor). The invention also relates to nucleic acids encoding these antibodies, expression vectors, host cells and methods for their production, methods for the production of antibodies, pharmaceutical compositions containing the abovementioned antibody, and other therapeutically active compounds, methods for the treatment of diseases or disorders mediated by CSF-1R, applications of antibodies or their pharmaceutical compositions for the treatment of diseases or disorders mediated by CSF-1R, and the use of antibodies and other therapeutically active compounds for the treatment of CSF-1R-mediated diseases or disorders.
EFFECT: application of antibodies or their pharmaceutical compositions for the treatment of diseases or disorders mediated by CSF-1R.
59 cl, 18 dwg, 15 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
